ABVC BioPharma, Inc.
ABVC
$0.9145
-$0.1905-17.24%
| Weiss Ratings | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.27 | |||
| Price History | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 29.72% | |||
| 30-Day Total Return | 30.72% | |||
| 60-Day Total Return | 57.67% | |||
| 90-Day Total Return | 66.30% | |||
| Year to Date Total Return | 42.60% | |||
| 1-Year Total Return | -28.55% | |||
| 2-Year Total Return | -85.74% | |||
| 3-Year Total Return | -96.58% | |||
| 5-Year Total Return | -95.43% | |||
| 52-Week High % Change | -47.14% | |||
| 52-Week Low % Change | 128.62% | |||
| Price | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.73 | |||
| 52-Week Low Price | $0.40 | |||
| 52-Week Low Price (Date) | Feb 10, 2025 | |||
| 52-Week High Price (Date) | Apr 25, 2024 | |||
| Valuation | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 11.20M | |||
| Enterprise Value | 13.36M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.98 | |||
| Earnings Per Share Growth | -72.09% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 22.30 | |||
| Price/Book (Q) | 1.31 | |||
| Enterprise Value/Revenue (TTM) | 26.20 | |||
| Price | $0.91 | |||
| Enterprise Value/EBITDA (TTM) | -2.12 | |||
| Enterprise Value/EBIT | -2.11 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 12.41M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 510 668 0881 | |||
| Address | 44370 Old Warm Springs Boulevard Fremont, CA 94538 | |||
| Website | www.abvcpharma.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,238.87% | |||
| Profit Margin | -1,616.92% | |||
| Management Effectiveness | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -25.42% | |||
| Return on Equity | -- | |||
| Income Statement | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 500.50K | |||
| Total Revenue (TTM) | 509.80K | |||
| Revenue Per Share | $0.04 | |||
| Gross Profit (TTM) | 369.90K | |||
| EBITDA (TTM) | -6.29M | |||
| EBIT (TTM) | -6.32M | |||
| Net Income (TTM) | -8.24M | |||
| Net Income Avl. to Common (TTM) | -8.24M | |||
| Total Revenue Growth (Q YOY) | 2,348.43% | |||
| Earnings Growth (Q YOY) | 96.01% | |||
| EPS Diluted (TTM) | -0.98 | |||
| EPS Diluted Growth (Q YOY) | 97.56% | |||
| Balance Sheet | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 208.20K | |||
| Cash Per Share (Q) | $0.02 | |||
| Total Current Assets (Q) | 2.15M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 7.98M | |||
| Current Ratio (Q) | 0.340 | |||
| Book Value Per Share (Q) | $0.70 | |||
| Total Assets (Q) | 14.46M | |||
| Total Current Liabilities (Q) | 6.32M | |||
| Total Debt (Q) | 2.75M | |||
| Total Liabilities (Q) | 6.48M | |||
| Total Common Equity (Q) | 8.36M | |||
| Cash Flow | ABVC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 154.20K | |||
| Cash from Financing (TTM) | 1.49M | |||
| Net Change in Cash (TTM) | -351.10K | |||
| Levered Free Cash Flow (TTM) | -2.09M | |||
| Cash from Operations (TTM) | -1.80M | |||
